← Back to headlines
Barclays Initiates Bristol Myers with Overweight Rating on Pipeline Potential
Barclays has begun coverage of Bristol Myers (BMY) with an 'Overweight' rating, emphasizing the company's promising drug pipeline.
23 Feb, 18:13 — 23 Feb, 18:13
ℹOnly 1 source covers this story
